Copyright Reports & Markets. All rights reserved.

Global Non-opioid Pain Med Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Non-opioid Pain Med Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Diclofenac Sodium
    • 1.3.3 Acetaminophen
    • 1.3.4 Indomethacin
    • 1.3.5 Ibuprofen
    • 1.3.6 Aspirin
    • 1.3.7 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Non-opioid Pain Med Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Mild Pain
    • 1.4.3 Moderate Pain
  • 1.5 Global Non-opioid Pain Med Market Size & Forecast
    • 1.5.1 Global Non-opioid Pain Med Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Non-opioid Pain Med Sales Quantity (2021-2032)
    • 1.5.3 Global Non-opioid Pain Med Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 WEX Pharmaceuticals Inc.
    • 2.1.1 WEX Pharmaceuticals Inc. Details
    • 2.1.2 WEX Pharmaceuticals Inc. Major Business
    • 2.1.3 WEX Pharmaceuticals Inc. Non-opioid Pain Med Product and Services
    • 2.1.4 WEX Pharmaceuticals Inc. Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 WEX Pharmaceuticals Inc. Recent Developments/Updates
  • 2.2 BASF
    • 2.2.1 BASF Details
    • 2.2.2 BASF Major Business
    • 2.2.3 BASF Non-opioid Pain Med Product and Services
    • 2.2.4 BASF Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 BASF Recent Developments/Updates
  • 2.3 Xinhua Pharm
    • 2.3.1 Xinhua Pharm Details
    • 2.3.2 Xinhua Pharm Major Business
    • 2.3.3 Xinhua Pharm Non-opioid Pain Med Product and Services
    • 2.3.4 Xinhua Pharm Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Xinhua Pharm Recent Developments/Updates
  • 2.4 Johnson & Johnson（McNeil Consumer Healthcare）
    • 2.4.1 Johnson & Johnson（McNeil Consumer Healthcare） Details
    • 2.4.2 Johnson & Johnson（McNeil Consumer Healthcare） Major Business
    • 2.4.3 Johnson & Johnson（McNeil Consumer Healthcare） Non-opioid Pain Med Product and Services
    • 2.4.4 Johnson & Johnson（McNeil Consumer Healthcare） Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Johnson & Johnson（McNeil Consumer Healthcare） Recent Developments/Updates
  • 2.5 Granules Biocause
    • 2.5.1 Granules Biocause Details
    • 2.5.2 Granules Biocause Major Business
    • 2.5.3 Granules Biocause Non-opioid Pain Med Product and Services
    • 2.5.4 Granules Biocause Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Granules Biocause Recent Developments/Updates
  • 2.6 Novacyl
    • 2.6.1 Novacyl Details
    • 2.6.2 Novacyl Major Business
    • 2.6.3 Novacyl Non-opioid Pain Med Product and Services
    • 2.6.4 Novacyl Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Novacyl Recent Developments/Updates
  • 2.7 Pfizer
    • 2.7.1 Pfizer Details
    • 2.7.2 Pfizer Major Business
    • 2.7.3 Pfizer Non-opioid Pain Med Product and Services
    • 2.7.4 Pfizer Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Pfizer Recent Developments/Updates
  • 2.8 Hisoar
    • 2.8.1 Hisoar Details
    • 2.8.2 Hisoar Major Business
    • 2.8.3 Hisoar Non-opioid Pain Med Product and Services
    • 2.8.4 Hisoar Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Hisoar Recent Developments/Updates
  • 2.9 Anant Pharmaceuticals Pvt. Ltd.
    • 2.9.1 Anant Pharmaceuticals Pvt. Ltd. Details
    • 2.9.2 Anant Pharmaceuticals Pvt. Ltd. Major Business
    • 2.9.3 Anant Pharmaceuticals Pvt. Ltd. Non-opioid Pain Med Product and Services
    • 2.9.4 Anant Pharmaceuticals Pvt. Ltd. Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Anant Pharmaceuticals Pvt. Ltd. Recent Developments/Updates
  • 2.10 Strides Shasun
    • 2.10.1 Strides Shasun Details
    • 2.10.2 Strides Shasun Major Business
    • 2.10.3 Strides Shasun Non-opioid Pain Med Product and Services
    • 2.10.4 Strides Shasun Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Strides Shasun Recent Developments/Updates
  • 2.11 SI Group
    • 2.11.1 SI Group Details
    • 2.11.2 SI Group Major Business
    • 2.11.3 SI Group Non-opioid Pain Med Product and Services
    • 2.11.4 SI Group Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 SI Group Recent Developments/Updates
  • 2.12 Elam Pharma
    • 2.12.1 Elam Pharma Details
    • 2.12.2 Elam Pharma Major Business
    • 2.12.3 Elam Pharma Non-opioid Pain Med Product and Services
    • 2.12.4 Elam Pharma Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Elam Pharma Recent Developments/Updates
  • 2.13 AdvaCare Pharma
    • 2.13.1 AdvaCare Pharma Details
    • 2.13.2 AdvaCare Pharma Major Business
    • 2.13.3 AdvaCare Pharma Non-opioid Pain Med Product and Services
    • 2.13.4 AdvaCare Pharma Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 AdvaCare Pharma Recent Developments/Updates
  • 2.14 IOL
    • 2.14.1 IOL Details
    • 2.14.2 IOL Major Business
    • 2.14.3 IOL Non-opioid Pain Med Product and Services
    • 2.14.4 IOL Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 IOL Recent Developments/Updates
  • 2.15 Jingye Group
    • 2.15.1 Jingye Group Details
    • 2.15.2 Jingye Group Major Business
    • 2.15.3 Jingye Group Non-opioid Pain Med Product and Services
    • 2.15.4 Jingye Group Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Jingye Group Recent Developments/Updates
  • 2.16 NS Chemicals
    • 2.16.1 NS Chemicals Details
    • 2.16.2 NS Chemicals Major Business
    • 2.16.3 NS Chemicals Non-opioid Pain Med Product and Services
    • 2.16.4 NS Chemicals Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 NS Chemicals Recent Developments/Updates
  • 2.17 Hunan Zhongnan Pharmaceutical
    • 2.17.1 Hunan Zhongnan Pharmaceutical Details
    • 2.17.2 Hunan Zhongnan Pharmaceutical Major Business
    • 2.17.3 Hunan Zhongnan Pharmaceutical Non-opioid Pain Med Product and Services
    • 2.17.4 Hunan Zhongnan Pharmaceutical Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Hunan Zhongnan Pharmaceutical Recent Developments/Updates
  • 2.18 Nanjing Pharmaceutical Factory
    • 2.18.1 Nanjing Pharmaceutical Factory Details
    • 2.18.2 Nanjing Pharmaceutical Factory Major Business
    • 2.18.3 Nanjing Pharmaceutical Factory Non-opioid Pain Med Product and Services
    • 2.18.4 Nanjing Pharmaceutical Factory Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Nanjing Pharmaceutical Factory Recent Developments/Updates
  • 2.19 Huayin Jinqiancheng Pharmaceutical Co., Ltd.
    • 2.19.1 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Details
    • 2.19.2 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Major Business
    • 2.19.3 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Non-opioid Pain Med Product and Services
    • 2.19.4 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Recent Developments/Updates
  • 2.20 Mallinckrodt Pharmaceuticals
    • 2.20.1 Mallinckrodt Pharmaceuticals Details
    • 2.20.2 Mallinckrodt Pharmaceuticals Major Business
    • 2.20.3 Mallinckrodt Pharmaceuticals Non-opioid Pain Med Product and Services
    • 2.20.4 Mallinckrodt Pharmaceuticals Non-opioid Pain Med Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Mallinckrodt Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Non-opioid Pain Med by Manufacturer

  • 3.1 Global Non-opioid Pain Med Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Non-opioid Pain Med Revenue by Manufacturer (2021-2026)
  • 3.3 Global Non-opioid Pain Med Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Non-opioid Pain Med by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Non-opioid Pain Med Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Non-opioid Pain Med Manufacturer Market Share in 2025
  • 3.5 Non-opioid Pain Med Market: Overall Company Footprint Analysis
    • 3.5.1 Non-opioid Pain Med Market: Region Footprint
    • 3.5.2 Non-opioid Pain Med Market: Company Product Type Footprint
    • 3.5.3 Non-opioid Pain Med Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Non-opioid Pain Med Market Size by Region
    • 4.1.1 Global Non-opioid Pain Med Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Non-opioid Pain Med Consumption Value by Region (2021-2032)
    • 4.1.3 Global Non-opioid Pain Med Average Price by Region (2021-2032)
  • 4.2 North America Non-opioid Pain Med Consumption Value (2021-2032)
  • 4.3 Europe Non-opioid Pain Med Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Non-opioid Pain Med Consumption Value (2021-2032)
  • 4.5 South America Non-opioid Pain Med Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Non-opioid Pain Med Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 5.2 Global Non-opioid Pain Med Consumption Value by Type (2021-2032)
  • 5.3 Global Non-opioid Pain Med Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 6.2 Global Non-opioid Pain Med Consumption Value by Application (2021-2032)
  • 6.3 Global Non-opioid Pain Med Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 7.2 North America Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 7.3 North America Non-opioid Pain Med Market Size by Country
    • 7.3.1 North America Non-opioid Pain Med Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Non-opioid Pain Med Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 8.2 Europe Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 8.3 Europe Non-opioid Pain Med Market Size by Country
    • 8.3.1 Europe Non-opioid Pain Med Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Non-opioid Pain Med Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Non-opioid Pain Med Market Size by Region
    • 9.3.1 Asia-Pacific Non-opioid Pain Med Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Non-opioid Pain Med Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 10.2 South America Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 10.3 South America Non-opioid Pain Med Market Size by Country
    • 10.3.1 South America Non-opioid Pain Med Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Non-opioid Pain Med Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Non-opioid Pain Med Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Non-opioid Pain Med Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Non-opioid Pain Med Market Size by Country
    • 11.3.1 Middle East & Africa Non-opioid Pain Med Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Non-opioid Pain Med Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Non-opioid Pain Med Market Drivers
  • 12.2 Non-opioid Pain Med Market Restraints
  • 12.3 Non-opioid Pain Med Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Non-opioid Pain Med and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Non-opioid Pain Med
  • 13.3 Non-opioid Pain Med Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Non-opioid Pain Med Typical Distributors
  • 14.3 Non-opioid Pain Med Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Non-opioid Pain Med market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Non-opioid Pain Med market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Non-opioid Pain Med market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Non-opioid Pain Med market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Non-opioid Pain Med market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Non-opioid Pain Med market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Non-opioid Pain Med
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Non-opioid Pain Med market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include WEX Pharmaceuticals Inc., BASF, Xinhua Pharm, Johnson & Johnson（McNeil Consumer Healthcare）, Granules Biocause, Novacyl, Pfizer, Hisoar, Anant Pharmaceuticals Pvt. Ltd., Strides Shasun, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Non-opioid Pain Med market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Diclofenac Sodium
    Acetaminophen
    Indomethacin
    Ibuprofen
    Aspirin
    Others
    Market segment by Application
    Mild Pain
    Moderate Pain
    Major players covered
    WEX Pharmaceuticals Inc.
    BASF
    Xinhua Pharm
    Johnson & Johnson（McNeil Consumer Healthcare）
    Granules Biocause
    Novacyl
    Pfizer
    Hisoar
    Anant Pharmaceuticals Pvt. Ltd.
    Strides Shasun
    SI Group
    Elam Pharma
    AdvaCare Pharma
    IOL
    Jingye Group
    NS Chemicals
    Hunan Zhongnan Pharmaceutical
    Nanjing Pharmaceutical Factory
    Huayin Jinqiancheng Pharmaceutical Co., Ltd.
    Mallinckrodt Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Non-opioid Pain Med product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Non-opioid Pain Med, with price, sales quantity, revenue, and global market share of Non-opioid Pain Med from 2021 to 2026.
    Chapter 3, the Non-opioid Pain Med competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Non-opioid Pain Med breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Non-opioid Pain Med market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Non-opioid Pain Med.
    Chapter 14 and 15, to describe Non-opioid Pain Med sales channel, distributors, customers, research findings and conclusion.

    Buy now